LinkMik Pharmaceutical recently secured nearly 100 million RMB in financing, led by CICC Private Equity, with participation from Chengming Capital and existing investors Fuhui Venture Capital and Ruihe Capital. This funding will support the development, production, and registration of innovative formulations, and expedite the commercialization and market promotion of its core products.
High sales cost of Pharmaceutical Listed Enterprises
EqualOcean reports that LindMik Pharma has recently secured nearly 100 million yuan in funding. The round was led by China International Capital Corporation Private Equity (CICC PE), with participation from Chengming Capital. Existing investors Fuhui Venture Capital and Ruihe Capital also increased their investments, and Haoyue Capital served as the exclusive financial advisor for this transaction. This round of financing will support the company's research, production, and registration of innovative formulations, with a focus on accelerating the commercialization and market promotion of its core products, Flurbiprofen Gel Patch and Loxoprofen Sodium Gel Patch.
The transdermal drug delivery field has always been a hotspot in pharmaceutical research due to its non-invasive nature, high patient compliance, and ability to provide stable drug release. "The current market for transdermal drug delivery is large and growing rapidly, with unlimited future potential. However, it faces high research barriers, complex preparation processes, and significant challenges in commercial production, leaving a substantial unmet clinical need," said Gu Danhui, Chairman of LindMik Pharma.
According to Equal Ocean, LindMik Pharma is a modern pharmaceutical company specializing in the research, development, and production of high-quality medications. Founded in 2001, the company is headquartered in a major industrial city in China. LindMik Pharma is dedicated to innovation and technology, aiming to improve global patient health. Its product portfolio spans several therapeutic areas, including cardiovascular diseases, diabetes, anti-infection, oncology, and neurological disorders.
As a high-tech enterprise, LindMik Pharma has made significant investments in research and development, establishing multiple R&D centers and collaborating with numerous renowned universities and research institutions both domestically and internationally. The company boasts an experienced research team focused on developing new drugs and treatment solutions. With advanced R&D technologies and strict quality control, LindMik Pharma's products have gained wide recognition in both domestic and international markets.
In terms of production, LindMik Pharma operates production facilities that meet international standards, utilizing the most advanced production equipment and technologies to ensure the safety and efficacy of each product batch. The company also actively promotes environmental protection and sustainable development strategies, striving to minimize the environmental impact of its production processes.
LindMik Pharma not only emphasizes product quality and technological innovation but also prioritizes corporate social responsibility. The company actively participates in philanthropic activities, supports the development of healthcare, and is committed to raising public health awareness.
Overall, with its outstanding R&D capabilities, stringent quality control, and strong sense of social responsibility, LindMik Pharma has become a significant player in the pharmaceutical industry and is gradually building a solid reputation in the international market.